Sanmai Technologies, a neurotechnology firm, has secured $12 million in funding led by LinkedIn co-founder Reid Hoffman, who will also join the company's board. Sanmai is focused on developing non-invasive ultrasound neurotherapeutics for mental health and neurological disorders. Their approach combines transcranial ultrasound stimulation with AI-driven software to provide safe and effective treatments.
The company's core technology utilises focused ultrasound and artificial intelligence to target and modulate brain activity. Sanmai's platform aims to address a range of mental health conditions. The recent investment will accelerate the development and clinical validation of Sanmai's neurotherapeutic solutions, potentially offering new avenues for treating neurological disorders.
Sanmai's Lotus MVP is the first FDA-cleared device using transcranial ultrasound to treat anxiety. This device has shown clinically significant reductions in anxiety for 71% of participants. Clinical effects are observed after eight sessions in treatment-resistant patients. The company is collaborating with the Acacia Clinics in Sunnyvale, CA and beyond to run the first double-blind, placebo-controlled trial. This device can be tailored to individual patients using brain MRI to target specific areas like the amygdala or posterior cingulate.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
